Status:
COMPLETED
Study Evaluating Bifeprunox in Bipolar Depression
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborating Sponsors:
Solvay Pharmaceuticals
Conditions:
Depression Bipolar
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of Bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
Eligibility Criteria
Inclusion
- Men and women 18 to 65 years of age, inclusive.
- Diagnosis of Bipolar Disorder and must be experiencing a depressive episode.
Exclusion
- This is a follow on study to protocol 3168A2-304. Only subjects who have participated in the previous study are eligible.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
380 Patients enrolled
Trial Details
Trial ID
NCT00245973
Start Date
June 1 2005
End Date
October 1 2007
Last Update
December 5 2007
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35216
2
Beverly Hills, California, United States, 90210
3
National City, California, United States, 91950
4
Stanford, California, United States, 94305